Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines

European Journal of Cancer

Volumn 41, Issue 15, 2005, Pages 2338-2346

  Loeffler Ragg, Judith ^a   Skvortsov, Sergej ^a   Sarg, Bettina ^b   Skvortsova, Ira ^b   Witsch Baumgartner, Martina ^b   Mueller, Doris ^a   Lindner, Herbert ^b   Zwierzina, Heinz ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Colorectal cancer; EGFR; Gefitinib; Proteomics; Resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID BINDING PROTEIN; GALECTIN 3; GEFITINIB; HEAT SHOCK PROTEIN 27; UBIQUITIN THIOLESTERASE;

ARTICLE; CANCER CELL CULTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENES, ERBB-1; HUMANS; PROTEIN KINASE INHIBITORS; PROTEOME; QUINAZOLINES; RECEPTOR, ERBB-3;

EID: 26244437966     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.06.014     Document Type: Article

References (44)

1. H.W. van Laarhoven, and C.J. Punt Systemic treatment of advanced colorectal carcinoma Eur J Gastroenterol Hepatol 16 3 2004 283 289
2. R.I. Nicholson, J.M. Gee, and M.E. Harper EGFR and cancer prognosis Eur J Cancer 37 Suppl 4 2001 S9 S15
3. J. Mendelsohn Targeting the epidermal growth factor receptor for cancer therapy J Clin Oncol 20 2002 1S 13S
4. Janmaat, and Giaccone Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors The Oncologist 8 2003 576 586
5. E.C. Douglass Development of ZD1839 in colorectal cancer Semin Oncol 30 3 Suppl 6 2003 17 22
6. F. Koizumi, F. Kanzawa, and Y. Ueda Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells Int J Cancer 108 3 2004 464 472
7. A. Azzariti, J.M. Xu, and L. Porcelli The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839) Biochem Pharmacol 68 1 2004 135 144
8. J.M. Xu, A. Azzariti, and G. Colucci The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines Cancer Chemother Pharmacol 52 6 2003 442 448
9. M. Daneshmand, D.A. Parolin, and H.W. Hirte A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients Clin Cancer Res 9 7 2003 2457 2464
10. H. Cortes-Funes, and H. Soto Parra Extensive experience of disease control with gefitinib and the role of prognostic markers Br J Cancer 89 2003 S3 S8
11. F.M. Sirotnak Studies with ZD1839 in preclinical models Semin Oncol 30 2003 12 20
12. J. Albanell, F. Rojo, and J. Baselga Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 Semin Oncol 28 5 Suppl 16 2001 56 66
13. N. Magne, J.L. Fischel, and A. Dubreuil Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa") Br J Cancer 86 9 2002 1518 1523
14. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New Engl J Med 350 21 2004 2129 2139
15. M. Olive, S. Untawale, and R.J. Coffey Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient In vitro cell dev biol 29 1993 239 248
16. R. Pai, B. Soreghan, and I.L. Szabo Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy Nat Med 8 3 2002 289 293
17. D. Darmoul, V. Gratio, and H. Devaud Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation J Biol Chem 279 20 2004 20927 20934
18. X. Wu, Z. Fan, and H. Masui Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin J Clin Invest 95 4 1995 1897 1905
19. H.W. Ott, H. Lindner, and B. Sarg Calgranulins in cystic fluid and serum from patients with ovarian carcinomas Cancer Res 63 21 2003 7507 7514
20. M.B. Resnick, J. Routhier, and T. Konkin Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study Clin Cancer Res 10 9 2004 3069 3075
21. M. Ranson, and S. Wardell Gefitinib, a novel, orally administered agent for the treatment of cancer J Clin Pharm Ther 29 2 2004 95 103
22. M.L. Janmaat, F.A. Kruyt, and J.A. Rodriguez Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin Cancer Res 9 6 2003 2316 2326
23. J.W. Lee, Y.H. Soung, and S.Y. Kim Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer Int J Cancer 113 3 2005 510 511
24. E. Tezel, K. Hibi, and T. Nagasaka PGP9.5 as a prognostic factor in pancreatic cancer Clin Cancer Res 6 12 2000 4764 4767
25. F. Brichory, D. Beer, and F. Le Naour Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer Cancer Res 61 21 2001 7908 7912
26. T. Yamazaki, and K. Hibi PGP9.5 as a marker for invasive colorectal cancer Clin Cancer Res 8 1 2002 192 195
27. Y. Liu, and H.A. Lashuel Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line Chem Biol 10 9 2003 837 846
28. O.L. Caballero, V. Resto, and M. Patturajan Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1) Oncogene 21 19 2002 3003 3010
29. T. Otsuki, K. Yata, and A. Takata-Tomokuni Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells Br J Haematol 127 3 2004 292 298
30. D. Busse, R.S. Doughty, and T.T. Ramsey Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity J Biol Chem 275 10 2000 6987 6995
31. Y.J. Lee, Y.K. Song, and J.J. Song Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt Exp Cell Res 288 1 2003 21 34
32. A. Harbottle, A.K. Daly, and K. Atherton Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance Int J Cancer 92 6 2001 777 783
33. K. Miyanishi, and T. Takayama Glutathione S-transferase-pi overexpression is closely associated with K-ras mutation during human colon carcinogenesis Gastroenterology 121 4 2001 865 874
34. Z. Yin, V.N. Ivanov, and H. Habelhah Glutathione S-transferase p elicits protection against H2O2-induced cell death via coordinated regulation of stress kinases Cancer Res 60 15 2000 4053 4057
35. J.F. Glatz, and G.J. van der Vusse Cellular fatty acid-binding proteins: their function and physiological significance Prog Lipid Res 35 3 1996 243 282
36. T. Bratt Lipocalins and cancer Biochim Biophys Acta 1482 1-2 2000 318 326
37. P. Sinha, G. Hutter, and E. Kottgen Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas Electrophoresis 20 14 1999 2952 2960
38. K. Kato, H. Ito, and I. Iwamoto Protein kinase inhibitors can suppress stress-induced dissociation of Hsp27 Cell Stress Chaperon 6 1 2001 16 20
39. C. Garrido, E. Schmitt, and C. Cande HSP27 and HSP70: potentially oncogenic apoptosis inhibitors Cell Cycle 2 6 2003 579 584
40. S. Oesterreich, C.N. Weng, and M. Qiu The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines Cancer Res 53 19 1993 4443 4448
41. K. Yamamoto, A. Okamoto, and S. Isonishi Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance Cancer Lett 168 2 2001 173 181
42. M.J. Rane, Y. Pan, and S. Singh Heat shock protein 27 controls apoptosis by regulating Akt activation J Biol Chem 278 30 2003 27828 27835
43. A. Citri, J. Gan, and Y. Mosesson Hsp90 restrains ErbB-2/HER2 signaling by limiting heterodimer formation EMBO Rep 5 12 2004 1165 1170
44. D. Chauhan, G. Li, and R. Shringarpure Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells Cancer Res 63 19 2003 6174 6177